Recently, Eli Lilly introduced a promising new oral GLP-1 receptor agonist called orforglipron, which has significantly piqued my professional curiosity
Reputable vendors and serious researchers avoid drawing conclusions beyond what controlled studies support
NAC is essentially a stabilized form of cysteine that your gut absorbs and converts back to L-cysteine, which then feeds glutathione production
Summary: GLP-1 dosing is individualised and varies by medication, with semaglutide (Ozempic) typically starting at 0.25 mg weekly and increasing to 0.52 mg, whilst liraglutide (Victoza) starts at 0.6 mg daily and increases to 1.21.8 mg, always following gradual escalation protocols determined by your prescriber
Although clinical trials with GLP-1 agonists are still ongoing, these findings suggested that GLP-1 receptor agonists could represent a useful tool in the management of patients with PWS, with promising effects on hyperphagia and body weight [49]